Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists

Pharmacology and Therapeutics

Volumn 127, Issue 2, 2010, Pages 175-188

  Dufton, Neil ^a   Perretti, Mauro ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Annexin A1; Endogenous anti inflammation; Formyl peptide; Neutrophil migration; New chemical entities; Novel therapeutics

Indexed keywords

ANTIFLAMMIN 2; BILE ACID; CATHEPSIN G; CYCLOSPORIN A; CYCLOSPORIN H; FORMYLPEPTIDE; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HUMANIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; LIPOXIN A; PIROXICAM; SERUM AMYLOID A; SPINORPHIN; ANTIINFLAMMATORY AGENT; FPR2 PROTEIN, HUMAN; LIPOXIN RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CELL MIGRATION; HAIR GROWTH; HUMAN; INFLAMMATION; NONHUMAN; ODOR; PAIN; PRIORITY JOURNAL; RESPIRATORY BURST; REVIEW; RHEUMATIC DISEASE; SMELLING; XENOBIOTIC METABOLISM; AGONISTS; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; MICE; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN;

EID: 77954218503     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.04.010     Document Type: Review

References (190)

1. Al-Mohanna F.A., Hallett M.B. Actin polymerization in neutrophils is triggered without a requirement for a rise in cytoplasmic Ca2+. Biochem J 1990, 266:669-674.
2. Ali H., Richardson R.M., Haribabu B., Snyderman R. Chemoattractant receptor cross-desensitization. J Biol Chem 1999, 274:6027-6030.
3. Ali H., Richardson R.M., Tomhave E.D., Didsbury J.R., Snyderman R. Differences in phosphorylation of formylpeptide and C5a chemoattractant receptors correlate with differences in desensitization. J Biol Chem 1993, 268:24247-24254.
4. Ambrose M.P., Bahns C.L., Hunninghake G.W. Lipocortin I production by human alveolar macrophages. Am J Respir Cell Mol Biol 1992, 6:17-21.
5. Andersson T., Dahlgren C., Pozzan T., Stendahl O., Lew P.D. Characterization of fMet-Leu-Phe receptor-mediated Ca2+ influx across the plasma membrane of human neutrophils. Mol Pharmacol 1986, 30:437-443.
6. Anton P.A., Targan S.R., Shanahan F. Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. Gastroenterology 1989, 97:20-28.
7. Arterburn J.B., Oprea T.I., Prossnitz E.R., Edwards B.S., Sklar L.A. Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. Curr Top Med Chem 2009, 9:1227-1236.
8. Babbin B.A., Laukoetter M.G., Nava P., Koch S., Lee W.Y., Capaldo C.T., et al. Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J Immunol 2008, 181:5035-5044.
9. Babbin B.A., Lee W.Y., Parkos C.A., Winfree L.M., Akyildiz A., Perretti M., et al. Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem 2006, 281:19588-19599.
10. Badolato R., Wang J.M., Murphy W.J., Lloyd A.R., Michiel D.F., Bausserman L.L., et al. Serum amyloid A is a chemoattractant: Induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994, 180:203-209.
11. Bae Y.S., Lee H.Y., Jo E.J., Kim J.I., Kang H.K., Ye R.D., et al. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol 2004, 173:607-614.
12. Baek S.H., Seo J.K., Chae C.B., Suh P.G., Ryu S.H. Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. J Biol Chem 1996, 271:8170-8175.
13. Banka C.L., Yuan T., de Beer M.C., Kindy M., Curtiss L.K., de Beer F.C. Serum amyloid A (SAA): Influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995, 36:1058-1065.
14. Baranova I.N., Vishnyakova T.G., Bocharov A.V., Kurlander R., Chen Z., Kimelman M.L., et al. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem 2005, 280:8031-8040.
15. Benditt E.P., Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A 1977, 74:4025-4028.
16. Bensalem N., Ventura A.P., Vallee B., Lipecka J., Tondelier D., Davezac N., et al. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. Mol Cell Proteomics 2005, 4:1591-1601.
17. Bjorkman L., Karlsson J., Karlsson A., Rabiet M.J., Boulay F., Fu H., et al. Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1. J Leukoc Biol 2008, 83:245-253.
18. Bonnans C., Gras D., Chavis C., Mainprice B., Vachier I., Godard P., et al. Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells. Biomed Pharmacother 2007, 61:261-267.
19. Borregaard N. Development of neutrophil granule diversity. Ann N Y Acad Sci 1997, 832:62-68.
20. Boulay F., Tardif M., Brouchon L., Vignais P. The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry 1990, 29:11123-11133.
21. Burli R.W., Xu H., Zou X., Muller K., Golden J., Frohn M., et al. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett 2006, 16:3713-3718.
22. Cash J.L., Christian A.R., Greaves D.R. Chemerin peptides promote phagocytosis in a ChemR23 and Syk-dependent manner. J Immunol 2010, 184:5315-5324.
23. Chatterjee B.E., Yona S., Rosignoli G., Young R.E., Nourshargh S., Flower R.J., et al. Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. J Leukoc Biol 2005, 78:639-646.
24. Chen K., Huang J., Liu Y., Gong W., Cui Y., Wang J.M. Synergy of TRIF-dependent TLR3 and MyD88-dependent TLR7 in up-regulating expression of mouse FPR2, a promiscuous G-protein-coupled receptor, in microglial cells. J Neuroimmunol 2009, 213:69-77.
25. Chen K., Le Y., Liu Y., Gong W., Ying G., Huang J., et al. Cutting Edge: A Critical Role for the G Protein-Coupled Receptor mFPR2 in Airway Inflammation and Immune Responses. J Immunol 2010, 184:3331-3335.
26. Cheng N., He R., Tian J., Ye P.P., Ye R.D. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 2008, 181:22-26.
27. Chiang N., Arita M., Serhan C.N. Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 2005, 73:163-177.
28. Chiang N., Serhan C.N., Dahlen S.E., Drazen J.M., Hay D.W., Rovati G.E., et al. The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006, 58:463-487.
29. Christenson K., Bjorkman L., Tangemo C., Bylund J. Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway independent of formyl peptide receptor-like 1. J Leukoc Biol 2008, 83:139-148.
30. Cilibrizzi A., Quinn M.T., Kirpotina L.N., Schepetkin I.A., Holderness J., Ye R.D., et al. 6-Methyl-2,4-Disubstituted Pyridazin-3(2H)-ones: A novel class of small-molecule agonists for formyl peptide receptors. J Med Chem 2009, 52:5044-5057.
31. Cirino G., Cicala C., Sorrentino L., Ciliberto G., Arpaia G., Perretti M., et al. Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. Br J Pharmacol 1993, 108:573-574.
32. Clish C.B., O'Brien J.A., Gronert K., Stahl G.L., Petasis N.A., Serhan C.N. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A 1999, 96:8247-8252.
33. Crumpton M.J., Dedman J.R. Protein terminology tangle. Nature 1990, 345:212.
34. Cui Y., Le Y., Yazawa H., Gong W., Wang J.M. Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease. J Leukoc Biol 2002, 72:628-635.
35. Cui Y.H., Le Y., Zhang X., Gong W., Abe K., Sun R., et al. Up-regulation of FPR2, a chemotactic receptor for amyloid beta 1-42 (A beta 42), in murine microglial cells by TNF alpha. Neurobiol Dis 2002, 10:366-377.
36. D'Acquisto F. On the adaptive nature of Annexin-A1. Curr Opin Pharmacol 2009, 9:521-528.
37. D'Acquisto F., Merghani A., Lecona E., Rosignoli G., Raza K., Buckley C.D., et al. Annexin-1 modulates T-cell activation and differentiation. Blood 2007, 109:1095-1102.
38. D'Acquisto F., Paschalidis N., Raza K., Buckley C.D., Flower R.J., Perretti M. Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4+ T cells. Rheumatology (Oxford) 2008, 47:636-639.
39. D'Acquisto F., Paschalidis N., Sampaio A.L., Merghani A., Flower R.J., Perretti M. Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells. Eur J Immunol 2007, 37:3131-3142.
40. D'Acquisto F., Perretti M., Flower R.J. Annexin-A1: A pivotal regulator of the innate and adaptive immune systems. Br J Pharmacol 2008.
41. Dalpiaz A., Spisani S., Biondi C., Fabbri E., Nalli M., Ferretti M.E. Studies on human neutrophil biological functions by means of formyl-peptide receptor agonists and antagonists. Curr Drug Targets Immune Endocr Metabol Disord 2003, 3:33-42.
42. Damazo A.S., Yona S., D'Acquisto F., Flower R.J., Oliani S.M., Perretti M. Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation. Am J Pathol 2005, 166:1607-1617.
43. Damazo A.S., Yona S., Flower R.J., Perretti M., Oliani S.M. Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J Immunol 2006, 176:4410-4418.
44. Devosse T., Guillabert A., D'Haene N., Berton A., De Nadai P., Noel S., et al. Formyl peptide receptor-like 2 is expressed and functional in plasmacytoid dendritic cells, tissue-specific macrophage subpopulations, and eosinophils. J Immunol 2009, 182:4974-4984.
45. Dufton N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H. B., Gray, M., et al. (2010 ). The anti-inflammatory role of the murine formyl peptide receptor Fpr2: ligand-specific effects on leukocyte responses and experimental inflammation J Immunol in press.
46. El Kebir D., Jozsef L., Filep J.G. Opposing regulation of neutrophil apoptosis through the formyl peptide receptor-like 1/lipoxin A4 receptor: Implications for resolution of inflammation. J Leukoc Biol 2008.
47. El Kebir D., Jozsef L., Khreiss T., Pan W., Petasis N.A., Serhan C.N., et al. Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: A novel mechanism for resolution of inflammation. J Immunol 2007, 179:616-622.
48. El Kebir D., Jozsef L., Pan W., Wang L., Petasis N.A., Serhan C.N., et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 2009, 180:311-319.
49. Ernst J.D., Hoye E., Blackwood R.A., Jaye D. Purification and characterization of an abundant cytosolic protein from human neutrophils that promotes Ca2(+)-dependent aggregation of isolated specific granules. J Clin Invest 1990, 85:1065-1071.
50. Fan X., Krahling S., Smith D., Williamson P., Schlegel R.A. Macrophage surface expression of annexins I and II in the phagocytosis of apoptotic lymphocytes. Mol Biol Cell 2004, 15:2863-2872.
51. Fiore S., Antico G., Aloman M., Sodin-Semrl S. Lipoxin A4 biology in the human synovium. Role of the ALX signaling pathways in modulation of inflammatory arthritis. Prostaglandins Leukot Essent Fatty Acids 2005, 73:189-196.
52. Fiore S., Maddox J.F., Perez H.D., Serhan C.N. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med 1994, 180:253-260.
53. Fiorucci S., Wallace J.L., Mencarelli A., Distrutti E., Rizzo G., Farneti S., et al. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A 2004, 101:15736-15741.
54. Flower R.J., Blackwell G.J. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979, 278:456-459.
55. Freer R.J., Day A.R., Radding J.A., Schiffmann E., Aswanikumar S., Showell H.J., et al. Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry 1980, 19:2404-2410.
56. Frohn M., Xu H., Zou X., Chang C., McElvaine M., Plant M.H., et al. New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation. Bioorg Med Chem Lett 2007, 17:6633-6637.
57. Fu H., Karlsson J., Bylund J., Movitz C., Karlsson A., Dahlgren C. Ligand recognition and activation of formyl peptide receptors in neutrophils. J Leukoc Biol 2006, 79:247-256.
58. Gallin J.I., Goldstein I.M., Snyderman R. Overview. Inflammation: Basic principles and clinical correlates 1992, 1-4. Raven Press Ltd, New York. J.I. Gallin, I.M. Goldstein (Eds.).
59. Gao J.L., Murphy P.M. Species and subtype variants of the N-formyl peptide chemotactic receptor reveal multiple important functional domains. J Biol Chem 1993, 268:25395-25401.
60. Gao J.L., Chen H., Filie J.D., Kozak C.A., Murphy P.M. Differential expansion of the N-formylpeptide receptor gene cluster in human and mouse. Genomics 1998, 51:270-276.
61. Gao J.L., Guillabert A., Hu J., Le Y., Urizar E., Seligman E., et al. F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor. J Immunol 2007, 178:1450-1456.
62. Gao J.L., Lee E.J., Murphy P.M. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J Exp Med 1999, 189:657-662.
63. Gavins F.N., Dalli J., Flower R.J., Granger D.N., Perretti M. Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation. Faseb J 2007, 21:1751-1758.
64. Gavins F.N., Kamal A.M., D'Amico M., Oliani S.M., Perretti M. Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct. Faseb J 2005, 19:100-102.
65. Gavins F.N., Yona S., Kamal A.M., Flower R.J., Perretti M. Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood 2003, 101:4140-4147.
66. Gerke V., Moss S.E. Annexins: From structure to function. Physiol Rev 2002, 82:331-371.
67. Gilbert T.L., Bennett T.A., Maestas D.C., Cimino D.F., Prossnitz E.R. Internalization of the human N-formyl peptide and C5a chemoattractant receptors occurs via clathrin-independent mechanisms. Biochemistry 2001, 40:3467-3475.
68. Gilroy D.W., Lawrence T., Perretti M., Rossi A.G. Inflammatory resolution: New opportunities for drug discovery. Nat Rev Drug Discov 2004, 3:401-416.
69. Grond-Ginsbach C., Hummel M., Wiest T., Horstmann S., Pfleger K., Hergenhahn M., et al. Gene expression in human peripheral blood mononuclear cells upon acute ischemic stroke. J Neurol 2008, 255:723-731.
70. Guilford W.J., Parkinson J.F. Second-generation beta-oxidation resistant 3-oxa-lipoxin A4 analogs. Prostaglandins Leukot Essent Fatty Acids 2005, 73:245-250.
71. Gunji T., Onouchi Y., Nagasawa T., Katagiri S., Watanabe H., Kobayashi H., et al. Functional polymorphisms of the FPR1 gene and aggressive periodontitis in Japanese. Biochem Biophys Res Commun 2007, 364:7-13.
72. -/- mouse. Faseb J 2003, 17:253-255.
73. Hartt J.K., Barish G., Murphy P.M., Gao J.L. N-formylpeptides induce two distinct concentration optima for mouse neutrophil chemotaxis by differential interaction with two N-formylpeptide receptor (FPR) subtypes. Molecular characterization of FPR2, a second mouse neutrophil FPR. J Exp Med 1999, 190:741-747.
74. Hashimoto A., Hayashi I., Murakami Y., Sato Y., Kitasato H., Matsushita R., et al. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. J Rheumatol 2007, 34:2144-2153.
75. Hashimoto A., Murakami Y., Kitasato H., Hayashi I., Endo H. Glucocorticoids co-interact with lipoxin A4 via lipoxin A4 receptor (ALX) up-regulation. Biomed Pharmacother 2007, 61:81-85.
76. Hayhoe R.P., Kamal A.M., Solito E., Flower R.J., Cooper D., Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: Indication of distinct receptor involvement. Blood 2006, 107:2123-2130.
77. He R., Sang H., Ye R.D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003, 101:1572-1581.
78. He R.L., Zhou J., Hanson C.Z., Chen J., Cheng N., Ye R.D. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009, 113:429-437.
79. Hecht I., Jiang R., Sampaio A.L., Hermesh C., Rutledge C., Shemesh R., et al. A novel peptide agonist of FPRL1 (ALX) displays anti-inflammatory and cardioprotective effects. J Pharmacol Exp Ther 2008, 328:426-434.
80. Huang J., Chen K., Huang J., Gong W., Dunlop N.M., Howard O.M., et al. Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Carcinogenesis 2009, 30:348-355.
81. Huet E., Boulay F., Barral S., Rabiet M.J. The role of beta-arrestins in the formyl peptide receptor-like 1 internalization and signaling. Cell Signal 2007, 19:1939-1948.
82. Huwiler A., Pfeilschifter J. Lipids as targets for novel anti-inflammatory therapies. Pharmacol Ther 2009, 124:96-112.
83. Jensen L.E., Whitehead A.S. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998, 334(Pt 3):489-503.
84. Jousilahti P., Salomaa V., Rasi V., Vahtera E., Palosuo T. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease-Baseline findings of the PAIS project. Atherosclerosis 2001, 156:451-456.
85. Kamal A.M., Flower R.J., Perretti M. An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem Inst Oswaldo Cruz 2005, 100(Suppl 1):39-47.
86. Kamal A.M., Hayhoe R.P., Paramasivam A., Cooper D., Flower R.J., Solito E., et al. Antiflammin-2 activates the human formyl-peptide receptor like 1. Sci World J 2006, 6:1375-1384.
87. Kishimoto T.K., Jutila M.A., Berg E.L., Butcher E.C. Neutrophil MAC-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 1989, 245:1238-1241.
88. Koga T., Torigoshi T., Motokawa S., Miyashita T., Maeda Y., Nakamura M., et al. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Lett 2008, 582:579-585.
89. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982, 389:39-48.
90. Lavigne M.C., Murphy P.M., Leto T.L., Gao J.L. The N-formylpeptide receptor (FPR) and a second G(i)-coupled receptor mediate fMet-Leu-Phe-stimulated activation of NADPH oxidase in murine neutrophils. Cell Immunol 2002, 218:7-12.
91. Le Y., Ye R.D., Gong W., Li J., Iribarren P., Wang J.M. Identification of functional domains in the formyl peptide receptor-like 1 for agonist-induced cell chemotaxis. Febs J 2005, 272:769-778.
92. Le Y., Gong W., Li B., Dunlop N.M., Shen W., Su S.B., et al. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 1999, 163:6777-6784.
93. Le Y., Gong W., Tiffany H.L., Tumanov A., Nedospasov S., Shen W., et al. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci 2001, 21:RC123.
94. Le Y., Oppenheim J.J., Wang J.M. Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev 2001, 12:91-105.
95. Lee H.Y., Jo S.H., Lee C., Baek S.H., Bae Y.S. Differential production of leukotriene B4 or prostaglandin E2 by WKYMVm or serum amyloid A via formyl peptide receptor-like 1. Biochem Pharmacol 2006, 72:860-868.
96. Levy B.D. Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot Essent Fatty Acids 2005, 73:231-237.
97. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7:678-689.
98. Liang T.S., Wang J.M., Murphy P.M., Gao J.L. Serum amyloid A is a chemotactic agonist at FPR2, a low-affinity N-formylpeptide receptor on mouse neutrophils. Biochem Biophys Res Commun 2000, 270:331-335.
99. Lim L.H., Solito E., Russo-Marie F., Flower R.J., Perretti M. Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: Effect of lipocortin 1. Proc Natl Acad Sci U S A 1998, 95:14535-14539.
100. Lindhorst E., Young D., Bagshaw W., Hyland M., Kisilevsky R. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim Biophys Acta 1997, 1339:143-154.
101. Liu Y., Cousin J.M., Hughes J., Van Damme J., Seckl J.R., Haslett C., et al. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 1999, 162:3639-3646.
102. Machado F.S., Esper L., Dias A., Madan R., Gu Y., Hildeman D., et al. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. J Exp Med 2008, 205:1077-1086.
103. Machado F.S., Johndrow J.E., Esper L., Dias A., Bafica A., Serhan C.N., et al. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med 2006, 12:330-334.
104. Maddox J.F., Serhan C.N. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: Selective inactivation by dehydrogenation and reduction. J Exp Med 1996, 183:137-146.
105. Maderna P., Godson C. Phagocytosis of apoptotic cells and the resolution of inflammation. Biochim Biophys Acta 2003, 1639:141-151.
106. Maderna P., Godson C. Taking insult from injury: Lipoxins and lipoxin receptor agonists and phagocytosis of apoptotic cells. Prostaglandins Leukot Essent Fatty Acids 2005, 73:179-187.
107. Maderna P., Godson C. Lipoxins: Resolutionary road. Br J Pharmacol 2009, 158:947-959.
108. Maderna P., Yona S., Perretti M., Godson C. Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J Immunol 2005, 174:3727-3733.
109. Maestes D.C., Potter R.M., Prossnitz E.R. Differential phosphorylation paradigms dictate desensitization and internalization of the N-formyl peptide receptor. J Biol Chem 1999, 274:29791-29795.
110. Mancuso F., Flower R.J., Perretti M. Leukocyte transmigration, but not rolling or adhesion, is selectively inhibited by dexamethasone in the hamster post-capillary venule. Involvement of endogenous lipocortin 1. J Immunol 1995, 155:377-386.
111. Maney P., Walters J.D. Formylpeptide receptor single nucleotide polymorphism 348T>C and its relationship to polymorphonuclear leukocyte chemotaxis in aggressive periodontitis. J Periodontol 2009, 80:1498-1505.
112. Mhyre T.R., Loy R., Tariot P.N., Profenno L.A., Maguire-Zeiss K.A., Zhang D., et al. Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol Aging 2008, 29:1631-1643.
113. Miele L., Cordella-Miele E., Facchiano A., Mukherjee A.B. Novel anti-inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I. Nature 1988, 335:726-730.
114. Migeotte I., Communi D., Parmentier M. Formyl peptide receptors: A promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev 2006, 17:501-519.
115. Migeotte I., Riboldi E., Franssen J.D., Gregoire F., Loison C., Wittamer V., et al. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J Exp Med 2005, 201:83-93.
116. Mills J.S., Miettinen H.M., Cummings D., Jesaitis A.J. Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu. J Biol Chem 2000, 275:39012-39017.
117. Mitchell S., Thomas G., Harvey K., Cottell D., Reville K., Berlasconi G., et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 2002, 13:2497-2507.
118. Morris T., Stables M., Gilroy D.W. New perspectives on aspirin and the endogenous control of acute inflammatory resolution. Sci World J 2006, 6:1048-1065.
119. Munishkina L.A., Fink A.L. Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. Biochim Biophys Acta 2007, 1768:1862-1885.
120. Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2008, 18:109-118.
121. Niederau C., Backmerhoff F., Schumacher B. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997, 44:90-107.
122. O'Hara R., Murphy E.P., Whitehead A.S., FitzGerald O., Bresnihan B. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 2004, 50:1788-1799.
123. Oliani S.M., Christian H.C., Manston J., Flower R.J., Perretti M. An immunocytochemical and in situ hybridization analysis of annexin 1 expression in rat mast cells: Modulation by inflammation and dexamethasone. Lab Invest 2000, 80:1429-1438.
124. Pepinsky R.B., Sinclair L.K., Browning J.L., Mattaliano R.J., Smart J.E., Chow E.P., et al. Purification and partial sequence analysis of a 37-kDa protein that inhibits phospholipase A2 activity from rat peritoneal exudates. J Biol Chem 1986, 261:4239-4246.
125. Perretti M. Lipocortin-derived peptides. Biochem Pharmacol 1994, 47:931-938.
126. Perretti M. Endogenous mediators that inhibit the leukocyte-endothelium interaction. Trends Pharmacol Sci 1997, 18:418-425.
127. Perretti M., Dalli J. Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics. Br J Pharmacol 2009, 158:936-946.
128. Perretti M., D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009, 9:62-70.
129. Perretti M., Ahluwalia A., Harris J.G., Goulding N.J., Flower R.J. Lipocortin-1 fragments inhibit neutrophil accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-CD11b monoclonal antibody. J Immunol 1993, 151:4306-4314.
130. Perretti M., Chiang N., La M., Fierro I.M., Marullo S., Getting S.J., et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 2002, 8:1296-1302.
131. Perretti M., Christian H., Wheller S.K., Aiello I., Mugridge K.G., Morris J.F., et al. Annexin I is stored within gelatinase granules of human neutrophil and mobilized on the cell surface upon adhesion but not phagocytosis. Cell Biol Int 2000, 24:163-174.
132. Perretti M., Flower R.J., Goulding N.J. The ability of murine leukocytes to bind lipocortin 1 is lost during acute inflammation. Biochem Biophys Res Commun 1993, 192:345-350.
133. Perretti M., Getting S.J., Solito E., Murphy P.M., Gao J.L. Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol 2001, 158:1969-1973.
134. Pieretti S., Di Giannuario A., De Felice M., Perretti M., Cirino G. Stimulus-dependent specificity for annexin 1 inhibition of the inflammatory nociceptive response: The involvement of the receptor for formylated peptides. Pain 2004, 109:52-63.
135. Planaguma A., Kazani S., Marigowda G., Haworth O., Mariani T.J., Israel E., et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008, 178:574-582.
136. Pouliot M., Clish C.B., Petasis N.A., Van Dyke T.E., Serhan C.N. Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: A role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 2000, 39:4761-4768.
137. Prossnitz E.R., Ye R.D. The N-formyl peptide receptor: A model for the study of chemoattractant receptor structure and function. Pharmacol Ther 1997, 74:73-102.
138. Rabiet M.J., Huet E., Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol 2005, 35:2486-2495.
139. Raynes J.G., McAdam K.P. Serum amyloid A isoforms in inflammation. Scand J Immunol 1991, 33:657-666.
140. Rigotti A., Acton S.L., Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995, 270:16221-16224.
141. Ritchie R.H., Gordon J.M., Woodman O.L., Cao A.H., Dusting G.J. Annexin-1 peptide Anx-1(2-26) protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemia. Br J Pharmacol 2005, 145:495-502.
142. Ritchie R.H., Sun X., Bilszta J.L., Gulluyan L.M., Dusting G.J. Cardioprotective actions of an N-terminal fragment of annexin-1 in rat myocardium in vitro. Eur J Pharmacol 2003, 461:171-179.
143. Romano M., Maddox J.F., Serhan C.N. Activation of human monocytes and the acute monocytic leukemia cell line (THP-1) by lipoxins involves unique signaling pathways for lipoxin A4 versus lipoxin B4: Evidence for differential Ca2+ mobilization. J Immunol 1996, 157:2149-2154.
144. Rosengarth A., Gerke V., Luecke H. X-ray structure of full-length annexin 1 and implications for membrane aggregation. J Mol Biol 2001, 306:489-498.
145. Rosengarth A., Luecke H. A calcium-driven conformational switch of the N-terminal and core domains of annexin A1. J Mol Biol 2003, 326:1317-1325.
146. Sahagun-Ruiz A., Colla J.S., Juhn J., Gao J.L., Murphy P.M., McDermott D.H. Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. Genes Immun 2001, 2:335-342.
147. Sandri S., Rodriguez D., Gomes E., Monteiro H.P., Russo M., Campa A. Is serum amyloid A an endogenous TLR4 agonist?. J Leukoc Biol 2008, 83:1174-1180.
148. Sarndahl E., Bergstrom I., Nijm J., Forslund T., Perretti M., Jonasson L. Enhanced neutrophil expression of annexin-1 in coronary artery disease. Metabolism 2010, 59:433-440.
149. Sawmynaden P., Perretti M. Glucocorticoid upregulation of the annexin-A1 receptor in leukocytes. Biochem Biophys Res Commun 2006, 349:1351-1355.
150. Scannell M., Flanagan M.B., deStefani A., Wynne K.J., Cagney G., Godson C., et al. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol 2007, 178:4595-4605.
151. Schaldach C.M., Riby J., Bjeldanes L.F. Lipoxin A4: A new class of ligand for the Ah receptor. Biochemistry 1999, 38:7594-7600.
152. Schiffmann E., Corcoran B.A., Wahl S.M. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A 1975, 72:1059-1062.
153. Schulz B., Liebisch G., Grandl M., Werner T., Barlage S., Schmitz G. Beta-amyloid (Abeta40, Abeta42) binding to modified LDL accelerates macrophage foam cell formation. Biochim Biophys Acta 2007, 1771:1335-1344.
154. Seifert R., Wenzel-Seifert K. The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors. Life Sci 2003, 73:2263-2280.
155. Sellar G.C., Oghene K., Boyle S., Bickmore W.A., Whitehead A.S. Organization of the region encompassing the human serum amyloid A (SAA) gene family on chromosome 11p15.1. Genomics 1994, 23:492-495.
156. Selvatici R., Falzarano S., Mollica A., Spisani S. Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils. Eur J Pharmacol 2006, 534:1-11.
157. Serhan C.N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity?. Prostaglandins 1997, 53:107-137.
158. Serhan C.N., Brain S.D., Buckley C.D., Gilroy D.W., Haslett C., O'Neill L.A., et al. Resolution of inflammation: State of the art, definitions and terms. Faseb J 2007, 21:325-332.
159. Serhan C.N., Hamberg M., Samuelsson B. Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A 1984, 81:5335-5339.
160. Serhan C.N., Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol 2005, 6:1191-1197.
161. Shah C., Hari-Dass R., Raynes J.G. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood 2006, 108:1751-1757.
162. Shen W., Proost P., Li B., Gong W., Le Y., Sargeant R., et al. Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines. Biochem Biophys Res Commun 2000, 272:276-283.
163. Solito E., de Coupade C., Parente L., Flower R.J., Russo-Marie F. Human annexin 1 is highly expressed during the differentiation of the epithelial cell line A 549: Involvement of nuclear factor interleukin 6 in phorbol ester induction of annexin 1. Cell Growth Differ 1998, 9:327-336.
164. Solito E., Kamal A., Russo-Marie F., Buckingham J.C., Marullo S., Perretti M. A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. Faseb J 2003, 17:1544-1546.
165. Song C., Shen Y., Yamen E., Hsu K., Yan W., Witting P.K., et al. Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. Atherosclerosis 2009, 202:596-604.
166. Southgate E.L., He R.L., Gao J.L., Murphy P.M., Nanamori M., Ye R.D. Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J Immunol 2008, 181:1429-1437.
167. Stockley R.A., Grant R.A., Llewellyn-Jones C.G., Hill S.L., Burnett D. Neutrophil formyl-peptide receptors. Relationship to peptide-induced responses and emphysema. Am J Respir Crit Care Med 1994, 149:464-468.
168. Strouse J.J., Young S.M., Mitchell H.D., Ye R.D., Prossnitz E.R., Sklar L.A., et al. A novel fluorescent cross-reactive formylpeptide receptor/formylpeptide receptor-like 1 hexapeptide ligand. Cytometry A 2009, 75:264-270.
169. Su S.B., Gong W., Gao J.L., Shen W., Murphy P.M., Oppenheim J.J., et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999, 189:395-402.
170. Tasaka K., Hamada M., Mio M. Inhibitory effect of interleukin-2 on histamine release from rat mast cells. Agents and Actions 1994, 41:C26-C27.
171. Tsao F.H., Meyer K.C., Chen X., Rosenthal N.S., Hu J. Degradation of annexin I in bronchoalveolar lavage fluid from patients with cystic fibrosis. Am J Respir Cell Mol Biol 1998, 18:120-128.
172. Tsuruki T., Takahata K., Yoshikawa M. Mechanism of the protective effect of intraperitoneally administered agonists for formyl peptide receptors against chemotherapy-induced alopecia. Biosci Biotechnol Biochem 2007, 71:1198-1202.
173. Vedder N.B., Harlan J.M. Increased surface expression of CD11b/CD18 (Mac-1) is not required for stimulated neutrophil adherence to cultured endothelium. J Clin Invest 1988, 81:676-682.
174. von Andrian U.H., Berger E.M., Ramezani L., Chambers J.D., Ochs H.D., Harlan J.M., et al. In vivo behavior of neutrophils from two patients with distinct inherited leukocyte adhesion deficiency syndromes. J Clin Invest 1993, 91:2893-2897.
175. Vong L., D'Acquisto F., Pederzoli-Ribeil M., Lavagno L., Flower R.J., Witko-Sarsat V., et al. Annexin 1 cleavage in activated neutrophils: A pivotal role for proteinase 3. J Biol Chem 2007, 282:29998-30004.
176. Vreugdenhil A.C., Dentener M.A., Snoek A.M., Greve J.W., Buurman W.A. Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol 1999, 163:2792-2798.
177. Wallner B.P., Mattaliano R.J., Hession C., Cate R.L., Tizard R., Sinclair L.K., et al. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 1986, 320:77-81.
178. Walther A., Riehemann K., Gerke V. A novel ligand of the formyl peptide receptor: Annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell 2000, 5:831-840.
179. Walzog B., Gaehtgens P. Adhesion molecules: The path to a new understanding of acute inflammation. News Physiol Sci 2000, 15:107-113.
180. ?/? mouse: Phenotypic studies. Annexins 2004, 1:109-120.
181. Wenzel-Seifert K., Hurt C.M., Seifert R. High constitutive activity of the human formyl peptide receptor. J Biol Chem 1998, 273:24181-24189.
182. Westermark G.T., Westermark P. Serum amyloid A and protein AA: Molecular mechanisms of a transmissible amyloidosis. FEBS Lett 2009, 583:2685-2690.
183. Wilson P.G., Thompson J.C., Webb N.R., de Beer F.C., King V.L., Tannock L.R. Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 2008, 173:1902-1910.
184. Witko-Sarsat V., Rieu P., Descamps-Latscha B., Lesavre P., Halbwachs-Mecarelli L. Neutrophils: Molecules, functions and pathophysiological aspects. Lab Invest 2000, 80:617-653.
185. Xue M., Hsieh G., Raymond-Stintz M.A., Pfeiffer J., Roberts D., Steinberg S.L., et al. Activated N-formyl peptide receptor and high-affinity IgE receptor occupy common domains for signaling and internalization. Mol Biol Cell 2007, 18:1410-1420.
186. Ye R.D., Boulay F., Wang J.M., Dahlgren C., Gerard C., Parmentier M., et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) family. Pharmacol Rev 2009.
187. Young S.M., Bologa C.M., Fara D., Bryant B.K., Strouse J.J., Arterburn J.B., et al. Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes. Cytometry A 2009, 75:253-263.
188. Zhang Y., Syed R., Uygar C., Pallos D., Gorry M.C., Firatli E., et al. Evaluation of human leukocyte N-formylpeptide receptor (FPR1) SNPs in aggressive periodontitis patients. Genes Immun 2003, 4:22-29.
189. Zhou C., Zhang S., Nanamori M., Zhang Y., Liu Q., Li N., et al. Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol 2007, 72:976-983.
190. Zouki C., Ouellet S., Filep J.G. The anti-inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells. Faseb J 2000, 14:572-580.